Healthcare
Live Price
Offline$4.08
+4.88% today
1Y Change
-26.47%
Window
Jun 23, 2025 → Jun 17, 2026
Coverage: 248 bars · Jun 23, 2025 → Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
TriSalus Life Sciences, Inc. (TLSI) is a Healthcare stock with a market cap of $170.00M and listed on NASDAQ. The stock last traded around $4.08 and down 26.5% across the available one-year price window (Jun 23, 2025 → Jun 17, 2026). Baseline metrics include revenue growth of +53.4%, EPS growth of -47.2%, a dividend yield of 0.0%. What stands out right now is revenue +53.4%, EPS -47.2%, free cash flow +54.0% with operating margin -59.7% and ROIC -112.3%. Valuation is more restrained than many high-expectation growth names at price/sales 3.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines TLSI price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
TLSI
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
TLSI Max Drawdown
-66.40%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for TLSI and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$8.4M
-32.2% YoY
FY Net Income
-$28.8M
+38.9% YoY
Free Cash Flow
-$24.0M
+27.6% YoY
Revenue Growth
+53.4%
EPS Growth
-47.2%
Gross Margin
84.6%
Net Margin
-86.9%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 45M | 29M | 19M | 12M | 8M |
| Gross Profit | 38M | 25M | 16M | 10M | 7M |
| Operating Income | -27M | -36M | -54M | -36M | -24M |
| EBITDA | -27M | -36M | -59M | -47M | -24M |
| Net Income | -39M | -33M | -59M | -47M | -29M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 20M | 9M | 12M | 9M | 30M |
| Total Assets | 35M | 24M | 25M | 22M | 38M |
| Total Liabilities | 69M | 50M | 52M | 34M | 7M |
| Shareholder Equity | -34M | -26M | -27M | -12M | 31M |
| Total Debt | 34M | 24M | 2M | 2M | 0 |
| Net Debt | 14M | 15M | -10M | -7M | -30M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
23M
+29.8% YoY
Capital Expenditures
1M
-60.1% YoY
Free Cash Flow
24M
+27.6% YoY
Key ratios
Gross Margin
84.6%
Operating Margin
-59.7%
Net Margin
-86.9%
ROE
137.2%
Debt / Equity
-1.02x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.